Candel Therapeutics, Inc.
CADL
$4.76
$0.224.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 15.76M | 646.00K | 4.85M | 3.42M | 22.71M |
| Gross Profit | -15.76M | -646.00K | -4.85M | -3.42M | -22.71M |
| SG&A Expenses | 3.27M | 3.49M | 3.72M | 3.93M | 3.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.40M | 8.76M | 8.57M | 7.90M | 9.93M |
| Operating Income | -7.40M | -8.76M | -8.57M | -7.90M | -9.93M |
| Income Before Tax | -14.07M | -10.65M | -22.24M | -8.22M | -11.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.07M | -10.65M | -22.24M | -8.22M | -11.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.07M | -10.65M | -22.24M | -8.22M | -11.10M |
| EBIT | -7.40M | -8.76M | -8.57M | -7.90M | -9.93M |
| EBITDA | -7.16M | -8.51M | -8.32M | -7.65M | -9.68M |
| EPS Basic | -0.40 | -0.33 | -0.74 | -0.28 | -0.38 |
| Normalized Basic EPS | -0.23 | -0.21 | -0.47 | -0.18 | -0.23 |
| EPS Diluted | -0.40 | -0.33 | -0.74 | -0.28 | -0.38 |
| Normalized Diluted EPS | -0.23 | -0.21 | -0.47 | -0.18 | -0.23 |
| Average Basic Shares Outstanding | 35.56M | 32.01M | 29.88M | 29.20M | 28.98M |
| Average Diluted Shares Outstanding | 35.56M | 32.01M | 29.88M | 29.20M | 28.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |